ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1089

Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Yeo jin lee1, Soo Min Ahn2, Ji Seon Oh3, Yong Gil Kim2, Chang Keun Lee2, Bin Yoo2 and Seokchan Hong2, 1Asan medical center, Seoul, Republic of Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 3Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV, presents with urinary abnormalities including hematuria and proteinuria, and is associated with the risk of chronic kidney disease (CKD). Despite the significance of persistent hematuria in AAV, the clinical value of proteinuria in the clinical course of AAV remains unknown. Therefore, we aimed to determine the prognostic significance of proteinuria monitoring in patients with AAV.

Methods: We retrospectively analyzed the data of patients who were diagnosed with AAV from March 2004 to August 2021 at a single tertiary center in Seoul, Korea. Kidney involvement of AAV was confirmed using kidney biopsy results. Birmingham Vasculitis Activity Score version 3.0 was used to evaluate the disease activity. Proteinuria was evaluated by a urine dipstick test. Poor renal outcome was defined as stage 4/5 CKD (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m2).

Results: A total of 77 patients with a median follow-up duration of 36 months (interquartile range, 18–79) were included in the study. Of them, 65 (84.4%) achieved remission after induction therapy. The patients were divided into two groups according to the presence of proteinuria at 6 months after induction therapy (n = 36 with proteinuria, 41 without proteinuria). After the remission of AAV, 13 of 65 patients relapsed, and there was no significant difference in the rate of relapse or death according to the presence of proteinuria (p=0.447 for relapse, 0.312 for death). In contrast, patients with proteinuria had significantly lower kidney function than did those without proteinuria (31 vs. 45 ml/min/1.73m², p=0.001). Multivariate analysis revealed that baseline kidney function (hazard ratio [HR], 0.962; 95% CI, 0.926–1.000, p=0.049) and proteinuria at 6 months (HR, 3.230; 95% CI, 1.042–10.008, p=0.042) were significantly associated with the development of stage 4/5 CKD.

Conclusion: The presence of proteinuria at 6 months after induction therapy and low renal function at baseline were significantly associated with the risk of severe CKD in patients with AAV. Monitoring for proteinuria after induction therapy may be helpful in predicting poor renal outcomes in patients with AAV.

Supporting image 1


Disclosures: Y. lee, None; S. Ahn, None; J. Oh, None; Y. Kim, None; C. Lee, None; B. Yoo, None; S. Hong, None.

To cite this abstract in AMA style:

lee Y, Ahn S, Oh J, Kim Y, Lee C, Yoo B, Hong S. Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prognostic-value-of-proteinuria-monitoring-in-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-value-of-proteinuria-monitoring-in-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology